Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 200.03 M
The data is delayed by 15 minutes.
Description: Agile Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, a once-weekly contraceptive patch, which is in Phase III clinical development. The company is also developing a pipeline of other new transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, a 28-day regimen, which provides a shortened hormone-free interval; and AG890, a levonorgestrel-only contraceptive patch for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||28.74 M||EPS||-1||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-3.67|
|P/E To EPS Growth||P/S||P/BV||4.1||Price/Cash Per Share|
|Price/Free Cash Flow||-13.7||ROA||-37.05%||ROE||-52.21%||ROI|
|Current Ratio||11.29||Quick Ratio||Long Term Debt/Equity||0.31||Debt Ratio||0.1|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||19.52 M||Cash From Investing Activities||-190 K||Cash From Operating Activities||-5.65 M||Gross Profit|
|Net Profit||-8.54 M||Operating Profit||-8.01 M||Total Assets||68.7 M||Total Current Assets||54.36 M|
|Total Current Liabilities||4.81 M||Total Debt||15.12 M||Total Liabilities||19.94 M||Total Revenue|
|High 52 week||5.37||Low 52 week||2.04||Last close||3.28||Last change||1.86%|
|RSI||30.73||Average true range||0.43||Beta||0.89||Volume||99.56 K|
|Simple moving average 20 days||-4.15%||Simple moving average 50 days||-22.43%||Simple moving average 200 days||-16.6%|
|Performance Week||15.49%||Performance Month||-32.51%||Performance Quart||-38.23%||Performance Half||-17.59%|
|Performance Year||28.13%||Performance Year-to-date||21.93%||Volatility daily||14.71%||Volatility weekly||32.9%|
|Volatility monthly||67.42%||Volatility yearly||233.55%||Relative Volume||435.39%||Average Volume||499.87 K|
|New High||New Low|
2020-05-07 08:36:12 | Is the Options Market Predicting a Spike in Agile Therapeutics AGRX Stock?
2020-05-06 20:19:45 | Edited Transcript of AGRX earnings conference call or presentation 5-May-20 8:30pm GMT
2020-05-05 16:01:10 | Agile Therapeutics Reports First Quarter 2020 Financial Results
2020-05-04 12:07:00 | Why Agile Therapeutics Stock Is Jumping Today
2020-04-22 08:00:10 | Agile Therapeutics Announces Changes to its Board of Directors
2020-04-01 17:50:09 | Agile Therapeutics AGRX Flat As Market Sinks: What You Should Know
2020-03-23 16:31:20 | Agile Therapeutics AGRX Stock Remains a Top Pick, Says Analyst
2020-03-18 08:49:12 | Implied Volatility Surging for Agile Therapeutics AGRX Stock Options
2020-03-15 16:02:02 | Weekly CFO Buys Highlight
2020-03-03 15:00:20 | 7 Cheap Stocks Under $7 With Massive Upside Potential
2020-02-21 12:00:05 | Agile Therapeutics AGRX Upgraded to Buy: Here's Why
2020-02-21 11:30:04 | Is Agile Therapeutics AGRX Stock Outpacing Its Medical Peers This Year?
2020-02-20 16:14:47 | Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
2020-02-20 16:01:10 | Agile Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-02-14 18:46:11 | FDA Approves Agile Therapeutics, Inc.’s Twirla® levonorgestrel and ethinyl estradiol Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin
2020-02-11 08:46:08 | Agile Finalizes $35M Term Loan Facility As Twirla PDUFA Date Looms
2020-02-03 13:30:16 | Attention Biotech Investors: Mark Your Calendar For These February PDUFA Dates
2020-01-09 06:19:11 | Buy Multibagger Stocks as Odds of a Rally Are High in 2020
2020-01-06 08:14:45 | Here's How to Play Stocks as US-Iran Tensions Mount
2020-01-02 08:00:10 | Agile Therapeutics Strengthens Commercial Leadership Team
2019-12-23 08:36:01 | Implied Volatility Surging for Agile Therapeutics AGRX Stock Options
2019-12-19 16:05:10 | Agile Therapeutics to Present at Biotech Showcase™ 2020 in San Francisco
2019-12-14 18:59:54 | Hedge Funds Have Never Been More Bullish On Agile Therapeutics Inc AGRX
2019-11-14 16:30:00 | Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
2019-11-11 16:40:43 | RBC: 3 Stock Picks Set to Soar 30%+
2019-11-04 11:24:17 | Agile AGRX Stock Surges Over 370%, What’s Next?
2019-10-31 10:52:11 | Agile Therapeutics Rallies After FDA Panel Backs Contraceptive Patch
2019-10-31 08:34:49 | Benzinga Pro's Top 5 Stocks To Watch For Thurs., Oct. 31, 2019: AAPL, FB, AGRX, X, CROX
2019-10-29 17:24:30 | Agile AGRX: Should You Catch this Falling Knife?
2019-10-28 08:00:05 | Agile Therapeutics Reports Third Quarter 2019 Financial Results
2019-10-25 09:30:01 | Is Agile Therapeutics AGRX Outperforming Other Medical Stocks This Year?
2019-10-25 09:00:01 | Agile Therapeutics AGRX Upgraded to Buy: Here's What You Should Know
2019-10-24 15:57:22 | 5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts
2019-10-14 00:17:21 | 3 Top Biotech Stocks With Major Catalysts in October